

AD _____

GRANT NO: DAMD17-94-J-4069


TITLE: Wnt Proteins in Mammary Epithelial Cell Transformation

PRINCIPAL INVESTIGATOR: Jan Kitajewski
Martin Julius
Zhili Zheng

CONTRACTING ORGANIZATION: Columbia University Health Sciences
New York, New York 10032

REPORT DATE: 6/15/95

TYPE OF REPORT: Annual



PREPARED FOR: U.S. Army Medical Research and Materiel
Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for public release;
distribution unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

19950801 020

DTIC QUALITY INSPECTED 1

REPORT DOCUMENTATION PAGE			Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503.				
1. AGENCY USE ONLY (Leave blank)	2. REPORT DATE 06/15/95	3. REPORT TYPE AND DATES COVERED Annual 06/01/94 - 05/31/95		
4. TITLE AND SUBTITLE Wnt Proteins in Mammary Epithelial Cell Transformation			5. FUNDING NUMBERS DAMD17-94-J-4069	
6. AUTHOR(S) Jan Kitajewski, Martin Julius, Zhili Zheng				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Columbia University Health Sciences 630 West 168th Street New York, NY 10032			8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012			10. SPONSORING/MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES				
12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for public release, distribution unlimited			12b. DISTRIBUTION CODE	
13. ABSTRACT (Maximum 200 words) We have assessed the ability of <i>Wnt-1</i> , <i>Wnt-2</i> , <i>Wnt-3</i> , <i>Wnt-3A</i> , <i>Wnt-4</i> , <i>Wnt-5A</i> , <i>Wnt-5B</i> , <i>Wnt-6</i> , <i>Wnt-7A</i> , and <i>Wnt-7B</i> to transform mammary epithelial cells. Epitope-tagged Wnt proteins were expressed in cells and the proteins were analyzed by immunoblots. Extracellular heparin-bound forms of <i>Wnt-1</i> , <i>Wnt-3A</i> , and <i>Wnt-5A</i> proteins were detected in culture supernatants. The transforming potential of Wnt proteins was tested using retroviral vectors to express genes in C57MG mammary epithelial cells. Paracrine transforming capability of <i>Wnt</i> genes was tested by co-cultivating mammary epithelial cells with <i>Wnt</i> -expressing Rat fibroblasts. Immunoblot analysis confirms the expression of Wnt proteins in all cell lines. Direct and paracrine transforming assays indicates that <i>Wnt-1</i> , <i>Wnt-2</i> , <i>Wnt-3</i> and <i>Wnt-3A</i> proteins transform mammary epithelial cells; <i>Wnt-7A</i> and <i>Wnt-7B</i> proteins partially transform; and <i>Wnt-4</i> , <i>Wnt-5A</i> , <i>Wnt-5B</i> , and <i>Wnt-6</i> proteins does not affect mammary epithelial cells. Wnt gene family members thus differ in their potential to morphologically transform mammary epithelial cells, suggesting several distinct receptors or quantitative differences in the signals different Wnt proteins provide.				
14. SUBJECT TERMS Wnt proteins, mammary oncogene, transformation, growth factors			15. NUMBER OF PAGES 19	
			16. PRICE CODE	
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT unlimited	

FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the US Army.

N/A Where copyrighted material is quoted, permission has been obtained to use such material.

N/A Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

✓ Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.


N/A In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and Use of Laboratory Animals of the Institute of Laboratory Resources, National Research Council (NIH Publication No. 86-23, Revised 1985).

N/A For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

✓ In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

✓ In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

✓ In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.


PI - Signature 6/23/95
Date

WNT PROTEINS IN MAMMARY EPITHELIAL TRANSFORMATION

Annual Report-1995

TABLE OF CONTENTS

INTRODUCTION	pages 2-6
BODY	pages 7-13
CONCLUSIONS	page 14
REFERENCES	pages 15-16

Accession For	
NTIS CRA&I	<input checked="" type="checkbox"/>
DTIC TAB	<input type="checkbox"/>
Unannounced	<input type="checkbox"/>
Justification	
By	
Distribution /	
Availability Codes	
Dist	Avail and/or Special
A-1	

INTRODUCTION

I. NATURE OF THE PROBLEM

There is strong evidence that Wnt proteins function as peptide growth factors that regulate the mammary gland growth cycle. Some of these proteins have already been shown to contribute to experimental mammary gland tumorigenesis in the mouse. Several groups are currently assessing whether *Wnt* genes play a role in the pathology of human mammary tumors, as might be predicted. Despite this evidence, work focused on the role of *Wnt* genes in breast cancer is in its infancy. The proposed studies are directly aimed at testing the hypothesis that *Wnt* genes encode regulators of normal and neoplastic mammary gland development.

The Wnt-1 protein is recognized as a mediator of cell-cell signaling events that can contribute to mammary tumorigenesis in the mouse. Despite accumulating evidence that Wnt-1 proteins act as growth factors, in the past it has been extremely difficult to purify Wnt-1 proteins in a soluble, cell-free form. For this reason, very little is known about Wnt specific cell surface receptors, which are proposed to be responsible for receiving signals from extracellular Wnt proteins. There is a pressing need to produce soluble, active Wnt ligands in order to understand the nature and regulation of Wnt-mediated growth control. In this proposal we will evaluate the hypothesis that *Wnt* genes encode a family of proteins that act as secreted growth factors that affect mammary epithelial cell physiology by interacting with cell surface receptors. It is expected that several of the Wnt proteins will demonstrably affect the growth properties of mammary epithelial cells, that these proteins act as secreted factors, and that they carry out their functions by stimulating specific cell-surface receptors on mammary epithelial cells.

II. BACKGROUND

The development of the mammary gland is a poorly understood process that consists of cycles of growth, morphogenesis, differentiation, and involution under the control of a variety of hormones and growth factors. On the basis of their ability to affect mammary gland growth and on their expression patterns, several peptide growth factors have been implicated as effectors of mammary gland development (reviewed in (1)). In many cases, deregulation of growth factor-stimulated signaling pathways contributes to the pathobiology of breast cancer (2, 3). The *Wnt* gene family encodes secretory proteins involved in cell growth and cell fate determination during murine embryogenesis, organogenesis, and oncogenesis. We are interested in the role of Wnt proteins in mammary gland development and oncogenesis.

Wnt family genes

The first *Wnt* genes to be cloned were identified based on their oncogenic effects in the mouse mammary gland. The *Wnt-1* gene (originally *int-1*(4)) was initially identified as a frequent target for insertional activation by mouse mammary tumor virus (MMTV) proviral DNA in MMTV-induced mammary gland tumors(5, 6). Inappropriate expression of the *Wnt-1* gene has been shown to contribute to mammary gland tumorigenesis(7, 8). One other *Wnt* gene, *Wnt-3*, was also originally identified as a transcriptionally activated oncogene in MMTV-induced mammary tumors(9). Most of the identified *Wnt* genes were isolated by

searching for genes homologous to *Wnt-1* using hybridization techniques(10, 11). and the polymerase chain reaction (PCR)(12). Each of the sequenced open reading frames encodes what appear to be cysteine-rich, secretory glycoproteins ranging from 350-380 amino acids. A comparison of the predicted amino acid sequences among murine *Wnt* gene family members reveal over 100 conserved residues fairly evenly distributed across the entire sequence and striking conservation of roughly 23 cysteines in nearly parallel positions. Different *Wnt* proteins are generally 40-60% identical at the amino acid level.

The normal functions of *Wnt* genes have been analyzed in several organisms; most extensively in those tractable to genetic or biochemical analysis of early development. Such studies have shown that *Wnt* proteins are involved in diverse developmental phenomena. The *Wnt-1* orthologue in *Drosophila* is the segment polarity gene *wingless* (13, 14). A combination of genetic and biochemical analyses, suggests that the *wg* protein functions as a local-acting, secreted factor that triggers a cascade of molecular events leading to the specification of segment polarity in the *Drosophila* embryo(15, 16, 17, 18). The *wg* protein has also been shown to have organizer activities that lead to specification of spatial patterns in adult structures, such as leg or wing(19, 20) and it is also involved in regulating neuroblast specification in the *Drosophila* central nervous system(21). In the frog, *Xenopus laevis*, several different *Wnt* genes have been shown to contribute to the experimental induction of dorsal mesoderm tissue and subsequent establishment of the body axis (22, 23, 24, 25). Current models of early embryonic patterning events in the frog propose the involvement of one or several *Wnt* proteins as determinants of dorsal axial position(25, 26). The murine *Wnt* genes cloned to date are expressed in spatially restricted patterns during gastrulation, neurulation, or early organogenesis. Of the *Wnt* genes analyzed, seven of the family members show restricted expression patterns in the developing brain, and several other family members are expressed in the neural tube and neural plate(27). On the basis of the analysis of *Wnt-1* gene deficiencies, the normal function of the murine *Wnt-1* gene is in proper development of the cerebellum and midbrain (28, 29, 30, 31). These observations have led to the proposal that murine *Wnt* proteins act either as mitogens or act to specify cell fate in the developing nervous system. *Wnt* proteins are also implicated in the process of limb development(27). Several *Wnt* genes are expressed in the developing limb and ectopic expression of *Wnt-1* in developing limbs of transgenic mice results in abnormalities in growth and skeletal patterning of the limb(32).

Wnt proteins and their mechanism of action

The predicted primary protein of the *Wnt-1* gene displays many of the characteristics of secreted growth factors: a hydrophobic signal peptide, a recognition site for signal peptidase, prospective sites of N-linked glycosylation, many cysteine residues, and lack of any identifiable membrane anchor domain(33). Due to the lack of cell lines expressing the endogenous *Wnt-1* gene, most of the work on the biochemical properties of *Wnt* proteins has been carried out with cells programmed to express exogenous *Wnt* cDNAs. In these ectopic settings, *Wnt-1* proteins behave as secretory glycoproteins, undergoing entry into the endoplasmic reticulum (ER), leader cleavage, and asparagine(N)-linked glycosylation at several sites(34, 35). Despite entry into the ER, *Wnt-1* proteins are very poorly secreted. Most of the *Wnt-1* protein remains associated with internal membranous components of cells. Intracellular *Wnt-1* is predominantly bound to BiP; a chaperonin-like protein found in the ER(36). A small portion of the most highly glycosylated forms of *Wnt-1* proteins is secreted(37, 38). The appearance of extracellular *Wnt-1* proteins is significantly enhanced by addition of heparin sulfate(37) or suramin(39) to the media. Such experiments suggest that

Wnt-1 proteins that have moved through the secretory pathway into the extracellular environment are not freely diffusible, but instead are tightly associated with either the cell surface(39) or the extracellular matrix(37). Although Wnt-1 proteins are not readily detected freely soluble in the media of cells expressing *Wnt-1* cDNA, evidence has accumulated that Wnt proteins can act in a paracrine fashion. First, entry into the secretory pathway is necessary for Wnt-1 biological activity(22, 40). Second, cell transformation assays have been developed that depend on paracrine effects of Wnt-1(40, 41). These paracrine assays involve co-cultivation of cells that do not exhibit responses to *Wnt-1* expression (fibroblast non-responsive cells) and mammary epithelial cell lines. When *Wnt-1* responsive cells (C57MG) are mixed with or surround Wnt-1 donor cells, they undergo morphological changes. Finally, analysis of *wg* protein function, the *Drosophila* homologue of *Wnt-1*, suggests that it acts in a paracrine fashion since the *wg* mutant phenotype is cell non autonomous(42); that is, mutant cells can be rescued by surrounding wild-type cells. These observations have led to the model that Wnt-1 proteins are local-acting factors that function to signal to cells that are adjacent or near the site of Wnt production but do not affect cells at sites distant from the site of production. In fact, Wnt-1 proteins tethered to the cell surface by addition of a transmembrane tail still exhibit autocrine and paracrine transforming activities(43, 44). Recently, it has been reported that Wnt-1 protein activity can be detected in the media of mammary epithelial cells programmed to express a *Wnt-1* cDNA (A.M.C. Brown, personal communication; J. Kitajewski, unpublished observations) suggesting that Wnt proteins can also act as diffusible secreted growth factors.

The Wnt-1 protein is now recognized as a mediator of cell-cell signaling events. Little is known regarding Wnt cell surface receptors or the nature of the signaling events triggered by receptor activation. Some clues have come from analysis of the *wg* signal transduction pathway in *Drosophila* embryos. *wg* expression is known to influence the expression of at least two homeobox-containing genes, *Distal-less* and *engrailed*(16). *wg* also affects the subcellular localization or levels of protein products encoded by another segmentation polarity gene, *armadillo*(*arm*). Armadillo is similar to the vertebrate proteins plakoglobin and b-catenin(45, 46), which are found associated with cadherins in desmosomes and adherens junctions. Wnts may therefore regulate the association of plakoglobin or b-catenin to the cadherin family of molecules or alternately cadherins and catenins may participate in transmitting Wnt-induced signals(47).

Wnt genes and mammary tumorigenesis

Abnormal expression of the *Wnt-1* gene products contributes to the development of mammary tumors(16). Transgenic mice expressing the *Wnt-1* gene in the mammary gland develop mammary tumors and these tumors have high levels of *Wnt-1* mRNA(7). Expression of the *Wnt-1* gene in two established mammary epithelial cell lines, C57MG cells(48) or RAC311C cells(49) leads to morphological transformation from flat cuboidal cells to highly refractile, elongated cells that continue to grow after confluence. In one of these cell lines, RAC cells, *Wnt-1* expression leads to increased tumorigenicity of the cells. In contrast, primary embryo cells and several established rodent fibroblast cell lines do not respond to *Wnt-1* expression. To date, *Wnt-1* mediated transformation appears to be restricted to mammary epithelial cells. There is also evidence that *Wnt* genes can contribute to mouse mammary tumorigenesis by gene amplification and resulting overexpression(9, 50). These studies have established that the *Wnt* genes are potent oncogenes in mouse mammary tumorigenesis.

Several lines of evidence suggest that the proteins encoded by the *Wnt* gene family may affect mammary gland development. Mice bearing a *Wnt-1* transgene that is expressed in the mammary gland exhibit extensive hormone-independent hyperplasia of mammary epithelium(7). In these mice, the glands of both virgin females and male animals resemble those of pregnant animals, and ovariectomy and adrenalectomy have no obvious effect on the morphology of these mammary hyperplasias(51). Both *Wnt-1* and *Wnt-3* expression can affect mammary gland growth; however, neither gene is expressed in the normal mammary gland. Since the mammary gland responds to both *Wnt-1* and *Wnt-3*, it has been proposed that they act through *Wnt* specific cell surface receptors found on mammary epithelial cells and that these receptors normally respond to proteins encoded by other *Wnt* gene family members that are expressed in the mammary gland. In fact, as shown in table 1, several *Wnt* genes are found to be expressed during post-natal development of the mammary gland(52, 53). Of the cloned and published *Wnt* genes, *Wnt-2*, *Wnt-4*, *Wnt-5A*, *Wnt-5B*, *Wnt-6*, and *Wnt-7A* are expressed in the mammary gland during periods of mammary gland growth and differentiation (in virgin and pregnant glands). In lactating glands, when the gland is no longer growing, none of the identified *Wnt* genes are expressed. These findings suggest that regulated expression of *Wnt* gene products may play a role in the normal expansion or differentiation of the mammary epithelium before lactation. The oncogenic effects of the *Wnt-1* and *Wnt-3* genes may thus interfere with the normal *Wnt*-mediated regulation of mammary gland growth.

Human *Wnt* Genes 2, 3, 4, and 7B have been found to be expressed in human breast cell lines and disease states of human breast tissue when compared to normal breast tissue. These results provide a strong rationale for studies on the action of *Wnt* proteins as a means of understanding the normal and neoplastic development of the mammary gland.

Table 1. Summary of temporal expression of *Wnt* genes in the mouse mammary gland*

	Virgin	Pregnancy			Lactation	
		Early	Mid	Late	Early	Late
<i>Wnt</i> -1	-	-	-	-	-	-
<i>Wnt</i> -2	+**	-	-	-	-	-
<i>Wnt</i> -3	-	-	-	-	-	-
<i>Wnt</i> -3A	-	-	-	-	-	-
<i>Wnt</i> -4	+	+	+	+	+	-
<i>Wnt</i> -5A	-	+	+	+	-	-
<i>Wnt</i> -5B	-	+	+	+	-	-
<i>Wnt</i> -6	-	+	+	+	+	-
<i>Wnt</i> -7A	-	-	-	-	-	-
<i>Wnt</i> -7B	+	+	+	-	-	-
*From reference (17) ** From reference (53)						

III. PURPOSE

The *overall objective* of the work proposed here is to determine how *Wnt* proteins modulate the growth of mammary epithelial cells, with the *long term goal* of understanding the role of *Wnt* genes in mammary tumorigenesis.

IV. METHODS OF APPROACH

Our *general strategy* is to carry out a study of the proteins encoded by ten different *Wnt* genes (*Wnt*-1, *Wnt*-2, *Wnt*-3, *Wnt*-3A, *Wnt*-4, *Wnt*-5A, *Wnt*-5B, *Wnt*-6, *Wnt*-7A, *Wnt*-7B) that will address the following *specific aims*:

1. *Examine the biochemical and secretory properties of Wnt proteins.* The coding potential for an antigenic epitope has been added to full length cDNAs encoding *Wnt*-1, *Wnt*-2, *Wnt*-3, *Wnt*-3A, *Wnt*-4, *Wnt*-5A, *Wnt*-5B, *Wnt*-6, *Wnt*-7A, and *Wnt*-7B. We will prepare stable cell lines expressing epitope-tagged *Wnt* proteins in order to determine how the biochemical properties of the proteins encoded by newly described *Wnt* genes compare to those described for *Wnt*-1 proteins. We will evaluate if these proteins enter the secretory pathway, how efficiently are they secreted, and once outside the cell are these proteins freely soluble, bound tightly to the extracellular matrix, or bound to the cell surface? Our goal is to identify *Wnt* proteins that can be purified for use as ligands.

2. *Determine the transforming potential of Wnt genes.* Using retroviral vectors to express the proteins encoded by these cDNAs in cultured cell lines, we have determined whether: (a) expression of these genes in cultured mammary epithelial cells leads to transformation, and (b) these proteins transmit signals in a paracrine fashion.

BODY


I. EXPERIMENTAL METHODS/RESULTS

Biochemical and secretory properties of Wnt proteins.

Epitope-tagging Wnt proteins. A key feature of the work proposed is to develop methods for the immunological detection and purification of proteins encoded by the *Wnt* gene family. Rather than generate antibodies against each of the Wnt proteins we have tagged Wnt proteins with an antigenic epitope for which well characterized, specific antibodies have already been generated; a process referred to as epitope tagging. Among the advantages of using epitope-tagged Wnt proteins in the experiments to be described is the ability to detect ectopically expressed Wnt proteins without the complications of detecting endogenously expressed Wnt proteins. The epitope we have chosen to add to Wnt proteins has the amino acid sequence YPYDVDPYA derived from the influenza HemAgglutinin (HA) protein and is recognized by monoclonal antibody 12CA5 (54)(the 12CA5 antibody will be referred to as the anti-HA antibody). In order to create vectors for the expression of epitope-tagged Wnt proteins, we have used site-directed mutagenesis to generate cDNAs encoding Wnt proteins fused in frame at their C-terminus to the amino acid sequence MAYPYDVDPYASLGPGP (the bold letters represent residues recognized by the anti-HA antibody). *Wnt* cDNAs were first subcloned into phagemid vectors (pBluescript from Promega) that have the sequences encoding the HA epitope situated downstream. Single strands were generated from the phagemid and used in a site-directed mutagenesis protocol with an oligonucleotide designed to loop-out the sequences between the last codon in the *Wnt* sequence and the first codon of the HA peptide to create a cDNA encoding the fusion protein. **Figure 1**, following page (pg. 8) displays an alignment of the amino acid sequences of Wnt proteins included in the analysis and the amino acid sequence of the added HA-epitope.

These cDNAs were then be subcloned into two different murine leukemia virus (MLV) based vectors, denoted LNCX vectors(55) and LINX . The LNCX vectors utilize the cytomegalovirus immediate early promoter/enhancer to drive expression of the gene of interest and the retroviral LTR to drive expression of the *neo* gene, which confers resistance to the drug G418. LNCX vectors were used to generate Rat fibroblast cell lines expressing different Wnt genes. LINX vectors were developed in our laboratory and utilize the HIV LTR as an internal promoter driving a bicistronic mRNA with a Wnt cDNA, followed by a poliovirus internal ribosome entry site (IRES), followed by a *neo* gene. We have also generated control retroviral vectors. As a positive control, we have used a vector expressing *Wnt-1* cDNA with no epitope-tag; this vector has been shown to be transforming. As negative controls, we have used the parental vector that does not contain a *Wnt* gene. **Figure 2**, shown below, displays the structure of the two retroviral vectors.

Figure 2. Schematic diagram of retroviral vectors, LNCX and LINX




WNT-1	-----M	GLWALLP	GWVSTTLL	LALTALP	AAALANSS	GRWGI	VNIASSTNL	L-TD	SKSLQ	LVLEPS	LQLLS	RKQRR	LIRQN																																																								
WNT-2	-----	-----	-----MN	VPLGGI	WLWLPL--L	LTWLT	PEVSSSWY	RATGG	--SR	VMCDNV	PGLVS	R--Q	RLCHRH																																																								
WNT-3	-----	-----	-----MEPH	LLGLLL	GLLLSGTRV	LAGYPI	WM--SL	ALGQ	QYTS	SLQPL	LCGSI	PGLVP	K--QLRFR																																																								
WNT-3A	-----	-----	-----M	APLGYL	LVLSLKQA	LGSYPI	WM--SL	ALGQ	QYTS	SLQPL	LCGSI	PGLVP	K--QLRFR																																																								
WNT-4	-----	-----	-----MSPR	SCLSLR	LLVFA-VF	SAASNL	--YLAKLS	SVGSI	--SE	ETCEKL	KGLI	Q--R	QVQMKRN																																																								
WNT-5A	-----	-----	-----	TAGGAM	SSFFLMAL	ATFFS	FAQVIE--A	NSW	SLG	MNPNV	QMS	EVII	--GA	QPLCSQL	AGLSQ	--Q	KKLCHLY																																																				
WNT-5B	-----	-----	-----	LRPAMP	SLLLVVA	ALLSS	WAQLLTD--A	NSW	SLAL	--NP	VQRP	EMFI	--GA	QPVCSQL	PGLSP	G--Q	RLCQLY																																																				
WNT-6	-----	-----	-----	-----	-----	MLPP	VPSSRLGL--LL	LLCP	PAH	VDGL	WNAV	GSPL	MD	TSICRKA	RLAGR	--Q	AEALCQAE																																																				
WNT-7A	-----	-----	-----	-----	-----	MTKR	ARRCLGH--L	FLSL	GI	VYLR	IGGFS	SVVAL	--GA	SIICNKI	PGLAP	R--Q	RAICQSR																																																				
WNT-7B	-----	-----	-----	-----	-----	MHRN	FRKIFY--V	FLCF	GVLY	VKLGALS	SVVAL	--GA	SIICNKI	PGLAP	R--Q	RAICQSR																																																					
WNT-1	PGILHS	VGGLOS	AV	RECKW	QFRNR	WNCP	T-AP	GPLH	FGKIVNR	GCRET	AFIFAITSAG	VTHS	VARS	CSEGSIE	SCTDY	-----	-----																																																				
WNT-2	PDMRAI	GLGVAEW	T	AECQ	HQFR	HRWN	CN	TLDR	HDLS	LAIF	GPVLDK	SSRES	AFV	YAISSAG	VFAIT	TRAC	SGELK																																																				
WNT-3	IEIMPS	VAEGV	KLGI	QECQ	HQFR	GRWN	CT	TIDDS	LAIF	GPVLDK	ATRES	AFV	YAISSAG	VFAIT	TRAC	SGELK	SCSDPK																																																				
WNT-3A	VEIMPS	VAEGV	KAGI	QECQ	HQFR	GRWN	CT	TVSN	LAIF	GPVLDK	ATRES	AFV	YAISSAG	VFAIT	TRAC	SGELK	ICGDS																																																				
WNT-4	LEVMD	SVRR	GALAI	ECCQ	YQFR	NRW	NCS	TL--	DSL	PVFK	VVTQ	GTRE	AFV	YAISSAG	VFAIT	TRAC	SSGELE																																																				
WNT-5A	QDHMOY	IGEG	AKTGM	KECQ	YQFR	HRW	NCS	TVD	--NT	SVF	GRVMOI	GSRET	AFV	YAISSAG	VFAIT	TRAC	SSGELE																																																				
WNT-5B	QEHMSY	IGEG	AKTGI	RECQ	HQFR	GRW	NCS	TVD	--NT	SVF	GRVMOI	GSRET	AFV	YAISSAG	VFAIT	TRAC	SSGELE																																																				
WNT-6	PEVVAE	LARG	ARLV	RECQ	FQFR	FRW	NCS	SH--	--SK	AF	GRVLOQ	DIRE	TA	VF	YAISSAG	ASHA	VTQ	ACSMGELL																																																			
WNT-7A	PDALIV	IGESQ	MGL	DECQ	FQFR	NRW	NCS	ALG	--ERT	VFG	KLKV	GSRE	AFV	YAISSAG	VFAIT	TRAC	SSGELE																																																				
WNT-7B	PDALIV	IGESQ	MGL	DECQ	FQFR	NRW	NCS	ALG	--ERT	VFG	KLKV	GSRE	AFV	YAISSAG	VFAIT	TRAC	SSGELE																																																				
WNT-1	-----	RRRG	P-----	GGPD	WHWG	CCSDN	IDF	RL	FG	REF	VDSG	E-----	KGR	DLR	FL	MNL	HNNEAGR	TTVF	SEMR	QECKCHG																																																	
WNT-2	-----	-----	-----	KD	SGT	FDWG	CCSDN	IDY	G	K	FAR	AFVDAK	ER-----	KG--	KDAR	A-----	LMNL	HNNEAGR	KAVR	FL	QECKCHG																																																
WNT-3	-----	-----	-----	GP	PEG	KWG	CCSDN	AD	F	VL	SREF	ADAR	EN-----	RP--	DAR	S-----	AMN	KNNEAGR	TTIL	DH	MHL	KCKCHG																																															
WNT-3A	-----	-----	-----	RLQ	SP	QEG	KWG	CCSDN	IE	F	GM	VSR	EFADAR	EN-----	RP--	DAR	S-----	AMN	KNNEAGR	QAI	A	SHMHL	KCKCHG																																														
WNT-4	-----	-----	-----	TVH	GSP	QEG	KWG	CCSDN	IAY	G	FA	SQ	FDVR	ER-----	SK--	GAS	SRAL	MNL	HNNEAGR	KAIL	TH	MR	VECKCHG																																														
WNT-5A	-----	-----	-----	ARP	KDL	PRD	WLWG	CCSDN	IDY	G	HP	FA	EFVDA	ER	ER	I	HAK	GSY	ESAR	I-----	LMNL	HNNEAGR	RTVY	NLA	ADVACKCHG																																												
WNT-5B	-----	-----	-----	ARP	KDL	PRD	WLWG	CCSDN	VEY	G	Y	FA	EFVDA	ER	ER	E	K	N	F	A	Q	SE	EQGR	A-----	LMNL	QNNNEAGR	RAVY	K	MAD	VACKCHG																																							
WNT-6	-----	-----	-----	SGLL	GT	PP	PGTCS	PD	ASA	A	EW	G	CCDD	VDF	G	E	K	S	R	L	F	MDAQ	HK-----	RG--	RGD	IR	--AL	VQL	HNNEAGR	LAV	S	H	TR	TECKCHG																																			
WNT-7A	-----	-----	-----	-----	-----	-----	-----	YH	D	E	G	K	W	G	CCSDN	IRY	G	I	G	F	A	K	VFVDA	EI-----	KQ--	NAR	T-----	LMNL	HNNEAGR	KILE	EN	M	K	LECKCHG																																			
WNT-7B	-----	-----	-----	-----	-----	-----	-----	YH	D	E	G	K	W	G	CCSDN	IRY	G	I	G	F	A	K	VFVDA	EI-----	KQ--	NAR	T-----	LMNL	HNNEAGR	KILE	EN	M	K	LECKCHG																																			
WNT-1	MSGCT	TV	TCW	MLP	TLRA	VD	LR	DRPDG	ASR	V	LYGN--	RG	SNR	ASRA	EL	LR	LE	PE	DP	HK	PP	S	PHD	LVYFEKS	PNF	CT	YS	GR	LG	TAGT																																							
WNT-2	VSGCT	LR	TCW	LMA	DFR	K	T	GEYL	WR	KYNG	AIQ	V	M	N	Q	D	TG--	FTVANKR	FKK	P	T	K	N	D	LVYFENS	PDY	C	I	R	D	EAGSLGT																																						
WNT-3	LSGCE	EV	K	TCW	MAQ	DFRA	I	G	D	F	L	K	D	K	YDS	ASE	M	V	E	K	H	R	S	R	G	W	VE-----	TL	R	A	K	YAL	FKP	P	T	D	LVYENS	PNF	C	E	P	N	P	E	T	G	S	F	G																				
WNT-3A	LSGCE	EV	K	TCW	MAQ	DFRT	I	G	D	F	L	K	D	K	YDS	ASE	M	V	E	K	H	R	S	R	G	W	VE-----	TL	R	A	K	YAL	FKP	P	T	D	LVYENS	PNF	C	E	P	N	P	E	T	G	S	F	G																				
WNT-4	VSGCE	EV	K	TCW	RAV	PFR	Q	V	G	H	A	L	K	E	F	D	G	ATE	V	E	P	R	R	V	G	S	R	AL	V-----	PR	NAQ	FKP	H	T	D	E	D	LVYLEPS	PDF	C	E	Q	I	R	S	G	V	L	G	T																			
WNT-5A	VSGC	SL	K	TCW	LQA	DFR	K	V	G	D	A	L	K	E	YDS	AA	M	R	L	N	S	R	G	K-----	LVQ	VNSR	FNS	P	T	Q	D	L	V	YDPS	PDY	C	L	R	N	E	T	T	G	S	L	G	T																						
WNT-5B	VSGC	SL	K	TCW	LQA	EF	R	K	V	G	D	R	L	K	E	YDS	AA	M	R	I	T	R	Q	G	K-----	LVQ	VNSR	FNS	P	T	Q	D	L	V	YDPS	PDY	C	L	R	N	E	T	T	G	S	L	G	T																					
WNT-6	LSG	C	A	L	S	T	C	W	Q	K	L	P	PF	RE	V	G	A	R	L	L	E	R	F	H	G	-----	ALL	PAV	R	T	K	P	G	R	A	D	L	L	Y	A	A	D	S	PD	F	C	A	P	N	R	R	T	G	S	P	G													
WNT-7A	VSGC	T	T	K	T	C	W	T	T	L	P	Q	RE	L	G	V	L	K	D	K	YNE	AV	H	V	E	P	R	A	S	R	N	K	R	P	TF-----	L	K	I	K	K	P	L	S	YR	K	P	M	D	T	D	L	V	I	E	L	S	PNY	C	E	E	D	P	V	T	G	S	V	G	T
WNT-7B	VSGC	T	T	K	T	C	W	T	T	L	P	Q	RE	L	G	V	L	K	D	K	YNE	AV	H	V	E	P	R	A	S	R	N	K	R	P	TF-----	L	K	I	K	K	P	L	S	YR	K	P	M	D	T	D	L	V	I	E	L	S	PNY	C	E	E	D	P	V	T	G	S	V	G	T
WNT-1	AGRA	C	N	S	S	P	A	L	D	G	C	EL	L	C	C	G	R	G	H	R	T	R	T	Q	R	-----	SCR	N	C	T	H	R	V	L	H	E	C	L	-----	SM	A	P	Y	D	V	D	P	D	Y	A	S	L	G	P	G	L													
WNT-2	AGRC	N	L	T	S	R	G	M	D	S	C	E	V	M	C	G	R	G	H	R	T	S	H	T	-----	R	M	T	C	E	C	K	F	H	W	C	C	A	V	-----	SM	A	P	Y	D	V	D	P	D	Y	A	S	L	G	P	G	L												
WNT-3	RDRT	C	N	V	T	S	H	G	I	D	G	C	D	L	L	C	C	G	R	G	H	N	A	R	T	E	K	E	K	C	H	V	F	H	W	C	C	V	-----	SM	A	P	Y	D	V	D	P	D	Y	A	S	L	G	P	G	L													
WNT-3A	RDRT	C	N	V	T	S	H	G	I	D	G	C	D	L	L	C	C	G	R	G	H	N	A	R	T	E	K	E	K	C	H	V	F	H	W	C	C	V	-----	SM	A	P	Y	D	V	D	P	D	Y	A	S	L	G	P	G	L													
WNT-4	RGR	C	N	K	T	S	K	A	I	D	G	C	EL	L	C	C	G	R	G	H	T	A	Q	V	E	LA	E	R	C	G	C	R	F	H	W	C	C	V	-----	SM	A	P	Y	D	V	D	P	D	Y	A	S	L	G	P	G	L													
WNT-5A	QGR	L	C	N	K	T	S	E	G	M	D	G	C	EL	M	C	C	G	R	G	H	T	A	Q	V	E	LA	E	R	C	G	C	R	F	H	W	C	C	V	-----	SM	A	P	Y	D	V	D	P	D	Y	A	S	L	G	P	G	L												
WNT-5B	QGR	L	C	N	K	T	S	E	G	M	D	G	C	EL	M	C	C	G	R	G	H	T	A	Q	V	E	LA	E	R	C	G	C	R	F	H	W	C	C	V	-----	SM	A	P	Y	D	V	D	P	D	Y	A	S	L	G	P	G	L												
WNT-6	RGR	A	C	N	S	S	A	P	D	L	S	G	C	D	L	L	C	C	G	R	G	H	R	Q	E	S	V	Q	LE	E	N	C	L	R	F	H	W	C	C	V	-----	SM	A	P	Y	D	V	D	P	D	Y	A	S	L	G	P	G	L											
WNT-7A	QGR	A	C	N	K	T	A	P	A	S	G	C	D	L	M	C	C	G	R	G	H	T	A	Q	V	E	LA	E	R	C	G	C	R	F	H	W	C	C	V	-----	SM	A	P	Y	D	V	D	P	D	Y	A	S	L	G	P	G	L												
WNT-7B	QGR	L	C	N	R	T	S	P	G	A	D	G	C	D	T	M	C	C	G	R	G	H	T	A	Q	V	E	LA	E	R	C	G	C	R	F	H	W	C	C	V	-----	SM	A	P	Y	D	V	D	P	D	Y	A	S	L	G	P	G	L											

Figure 1. Alignment of amino acid sequences of Wnt proteins with HA epitope at C-terminus (Engineered epitope = bold, HA epitope= bold/underlined).

Analysis of the biochemical and secretory properties of Wnt proteins was carried out in cell lines programmed to express these genes that were generated by infection with retroviral expression vectors. High-titer, helper free retroviral stocks were generated using the BOSC23 ecotropic virus packaging cell line(56). This cell line produces high titer retroviral stocks after transient transfection with retrovirus encoding plasmids ($>10^5$ colony forming units/ml) allowing rapid generation cell lines. The plasmids bearing Wnt-HA retroviral expression vectors were transfected into BOSC-23 cells, media was collected, and used to infect either C57MG mammary epithelial or Rat-1 fibroblast cell lines. These cell lines will be used to both analyze Wnt proteins (*Specific aim 1*) and to assess autocrine and paracrine transforming potential (*Specific aim 2*, see below).

Characterization of Wnt proteins. We have identified Wnt proteins in cell lines that are programmed to ectopically express the HA-tagged Wnt proteins. Protein expression was first evaluated in transiently transfected 293T cells. Cultured cells were transfected with 10 μ g of vector DNA and two days later protein expression was evaluated by immunoblot analysis to demonstrate that these cells are producing Wnt proteins. Cells were lysed in detergent (1% Triton-X100, in 10mm tris, 100mmNaCl), insoluble material was removed, and proteins in the lysate were fractionated on SDS-gels, transferred to nitrocellulose, and then subjected to immunoblot analysis using the anti-HA antibody. Proteins were be visualized on the immunoblots using Enhanced Chemiluminescence (ECL, Amersham). Extracts from control vector-infected cells were be used as a negative control for the immunoblot analysis.

Figure 3. Immunoblot of HA tagged Wnt proteins produced in transfected 293T cells.




The size of the Wnt proteins and the number of species detected is consistent with that predicted from the primary amino acid sequence of the ten Wnt proteins and the potential glycosylation sites identified in the sequence. In addition, roughly comparable levels of expression was seen for the ten Wnt proteins.

Analysis of secreted Wnt proteins. Extracellular Wnt-1 proteins are generally detected only after addition of compounds that can compete growth factors off extracellular

material. A number of growth factors and other secreted proteins are thought to associate with the extracellular matrix because of their affinity for heparin and/or heparin sulfate glycosaminoglycan. Extracellular Wnt-1 proteins can be detected as heparin-bound proteins (37). We have determined whether other Wnt proteins can be detected as heparin-bound species. Transiently transfected 293T cells expressing HA-tagged Wnt proteins were incubated 1 day post-transfection for 24 hours either in the absence or presence of soluble heparin-sulfate (100 μ g/ml). The media from the cells was spun at 10k X g for 10 minutes to remove intact cells, and the resulting media was centrifuged at 100k X g for 2 hours to pellet the heparin-sulfate. The heparin-sulfate pellet was resuspended in Laemli sample buffer and the proteins bound to heparin were analyzed by immunoblot analysis. We have detected extracellular heparin-bound forms of HA-tagged Wnt-1, Wnt-3A, and Wnt-5A proteins produced by transiently transfected cells (Figure 4).


Figure 4. Immunoblot analysis of Wnt-1, Wnt-3A, and Wnt-5A proteins produced in 293T cells. Extracellular, heparin-bound forms and intracellular forms.



The secretory potential of Wnt-1, Wnt-3A, and Wnt-5A proteins appears roughly equivalent. In order to detect these proteins, heparin addition was required indicating that each is bound to extracellular material.

Generation of Rat-1 fibroblasts expressing Wnt proteins. We and others have developed assays that specifically test for biological effects dependent on the secretion of Wnt-1 proteins. In these assays, paracrine activity is supplied by cell lines that are programmed to express Wnt proteins but which do not themselves detectably respond to these proteins (e.g., mouse 3T3 fibroblasts, Rat-1 fibroblasts, or HeLa cells). When mammary epithelial cells are placed in proximity to Wnt-1 donor fibroblast cell lines, the mammary epithelial cells become morphologically transformed. In order to test the paracrine transforming potential of *Wnt* gene family members we developed a panel of Rat-B1A fibroblasts that express the ten epitope-tagged Wnt proteins. For expression in Rat-B1A cells we have found that the CMV promoter efficiently drives expression of foreign genes; therefore we used a panel of LNCX based vectors bearing Wnt-HA cDNAs. The plasmids vectors were transfected into BOSC-23 cells, media was collected two days post-transfection, and used to infect Rat-B1A fibroblast cell lines. Selection (400 μ g/ml G418) was added two days after infection and colonies were pooled approximately 1 week after selection. Pooled colonies were used as a source of extracts to evaluate protein expression by immunoblot analysis, as described above. **Figure 5**, displays an immunoblot analysis of cell lines programmed to express Wnt-1, Wnt-2, Wnt-3, Wnt-3A, Wnt-4, Wnt-5A, Wnt-5B, Wnt-6, Wnt-7A, Wnt-7B.

Figure 5



All of these cells were expressing the epitope-tagged Wnt proteins. In the case of Wnt-4 and Wnt-5B, we repeated the generation of the cell line in a bid to get cells expressing higher amounts of Wnt protein; Wnt-4(b) and Wnt-5B(b) were cell lines developed that had higher levels of intracellular Wnt proteins.

The transforming potential of *Wnt* genes.

Wnt-1 and *Wnt-3* behave as mammary oncogenes when expressed in the mouse mammary gland. We know little about the biological activities of the proteins encoded by the newly identified *Wnt* genes, some of which are normally expressed in the developing mammary gland (see Table 1). The goal of *specific aim 2* is to use mammary epithelial transformation assays as a measure of the biological activity of *Wnt* proteins. We have compared the transforming activities of a subset of the murine *Wnt* gene family that includes *Wnt-1*, *Wnt-2*, *Wnt-3*, *Wnt-3A*, *Wnt-4*, *Wnt-5A*, *Wnt-5B*, *Wnt-6*, *Wnt-7A*, and *Wnt-7B*. These include genes expressed in the developing mammary gland (*Wnt-2*, *Wnt-4*, *Wnt-5A*, *Wnt-5B*, *Wnt-6*, and *Wnt-7B*) as well as genes not normally expressed in the mammary gland (*Wnt-1*, *Wnt-3*, *Wnt-3A*, and *Wnt-7A*).

Autocrine transformation by *Wnt* gene family members. To determine whether a *Wnt* gene has the potential to transform mammary epithelial cells, we have used retroviral vectors to generate cell lines ectopically expressing *Wnt* proteins (described in *specific aim 1*) and assessed the morphology and growth properties of these cells. Autocrine transforming potential was tested using the murine C57MG cell line(57). We have used the C57MG cell line extensively to study *Wnt-1* mediated transformation. The HIV LTR appears to function as a better promoter than the CMV promoter in the C57MG cell line (unpublished observations); therefore, we used a panel of LINX vectors with the ten epitope-tagged *Wnt* cDNAs to develop C57MG cell lines.

C57MG cells were infected with retroviral vectors, as described above, to generate cell lines programmed to express HA-tagged *Wnt* proteins (see *specific aim 1*). The transformed phenotype in these cells was evaluated by visibly assessing the morphology of confluent cultures, the results of the direct transformation assay are tabulated in Table II, and are discussed below.

Paracrine transformation by *Wnt* gene family members. *Wnt-1* proteins can affect mammary epithelial cells in a paracrine fashion(40, 41). We have determined if the proteins encoded by *Wnt* gene family members also act as paracrine effectors of mammary epithelial cell growth by generating Rat-B1A fibroblast cell lines that ectopically express HA-tagged *Wnt* proteins, see above and Figure 5. Paracrine assays were done by co-culturing *Wnt*-expressing Rat-1 cell lines with C57MG cells. The negative control in these paracrine transformation assays will be co-cultivation of uninfected Rat-1 cells with C57MG cells; this resulted in a flat monolayer composed of both cell types. The positive control was co-cultivation of *Wnt-1* expressing Rat-1 cells with C57MG cells, which results in morphological transformation of the mammary epithelial cells. Since the transformed cells continue to grow post-confluence the result of this assay is a culture that appears completely transformed. The results of this assay are tabulated in Table II. Our results indicate that HA-tagged *Wnt-1*, *Wnt-2*, *Wnt-3*, and *Wnt 3A* transform mammary epithelial cells. HA-tagged *Wnt-7A* and *Wnt-7B* gene expression leads to weak transformation of mammary epithelial cells. Finally, *Wnt-4*, *Wnt-5A*, *Wnt-5B*, and *Wnt-6* do not detectably transform mammary epithelial cells. These experiments also confirm that, in the case of *Wnt-1*, addition of the HA-epitope does not measurably affect the biological activity of these proteins. Paracrine assays were carried out for all ten *Wnt* genes using a set of Rat-B1A fibroblast cell lines as donors of *Wnt* activity. The results of the paracrine assays coincide with results obtained by direct expression in mammary epithelial cells. Our results indicate that there are two classes of *Wnt* proteins as evaluated by our assays in mammary epithelial cells; transforming *Wnt* genes and non-transforming *Wnt* genes. The *Wnt* proteins that are transforming all have the ability to

transform cells in a paracrine fashion demonstrating that the *Wnt* gene family encodes paracrine-acting growth factors.

Table II. Oncogenicity, Mammary gland expression, transforming potential of Wnt gene family members.

	<u>mammary gland</u>	<u>oncogenic</u>	<u>transforming</u> <u>direct</u>	<u>paracrine</u>
Wnt-1	-	+	+	+
Wnt-2	+ virgin, ducts		+	+
Wnt-3	-	+	+	+
Wnt-3A	-		+	+
Wnt-4	+ virgin, pregnant		-	-
Wnt-5A	+ pregnant		-	-
Wnt-5B	+ pregnant		-	-
Wnt-6	+ pregnant		-	-
Wnt-7A	-		+	+
Wnt-7B	+ virgin, pregnant		-/+	-/+

II. Goals of the Research

The data presented in this annual report represents results of experiments outlined in specific aim 1 and specific aim 2 of the research proposal. We feel we have completed approximately three-fourths of the work toward these goals and are currently evaluating the secretory potential of the Wnt proteins and determining if activity can be detected from conditioned media of cells expressing Wnt proteins. We have clearly segregated Wnt family members into two functional classes based upon their ability to transform cultured mammary epithelial cells.

CONCLUSIONS

In conclusion, we have segregated Wnt proteins into functional classes based upon their ability to transform mammary epithelial cells. This segregation may represent classes of Wnt proteins that interact with distinct Wnt-cell surface receptors. This may represent the first type of evidence that their may be distinct Wnt-cell surface receptors. Alternatively, one class may be involved in mitogenic stimulus and are thus are transforming, whereas the other class may be involved in differentiation of the mammary epithelium. Two interesting aspects of the segregation come out of this analysis. First, it appears that those Wnt genes either not normally expressed in the mammary gland (Wnt-1, Wnt-3, Wnt-3A, and Wnt-7B) or expressed at very low levels in the mammary gland (Wnt-2) are the most transforming. Whereas, those Wnt genes that are well expressed in the mammary gland (Wnt-4, Wnt-5A, Wnt-5B, Wnt-6) do not exhibit transformation activity. Second, when one compares the activity of the transforming genes to those reported to be overexpressed in mammary tumors(58) only one Wnt gene that is not transforming is overexpressed in this study. Wnt-2, Wnt-3, and Wnt-7B were all found to be transforming in our hands and have been found to be overexpressed in several mammary tumors; however, Wnt-4 never displayed transforming activity in our experiments but was found to be overexpressed in mammary tumors. Future work will be focused on assessing the activity of these proteins as soluble factors, identifying domains required for transforming activity, and searching for Wnt receptors in mammary epithelial cells.

REFERENCES

1. M. C. Neville, C. W. Daniel, *The Mammary Gland: Development, Regulation, and Function*. (Plenum Press, New York, 1987).
2. M. E. Lippman, R. E. Dickson, *Breast Cancer: Cellular and Molecular Biology* (Kluwer Academic Publishers, Boston/Dordrecht/London, 1988).
3. R. B. Dickson, M. E. Lippman, *GENES, ONCOGENES, AND HORMONES: Advances in Cellular and Molecular Biology of Breast Cancer, Cancer Treatment and Research* (Kluwer Academic Publishers, Norwell, 1992).
4. R. Nusse, et al., *Cell* **64**, 231 (1991).
5. R. Nusse, H. E. Varmus, *Cell* **31**, 99-109 (1982).
6. R. Nusse, A. van Ooyen, D. Cox, Y. K. Fung, H. Varmus, *Nature* **307**, 131-136 (1984).
7. A. S. Tsukamoto, R. Grosschedl, R. C. Guzman, T. Parslow, H. E. Varmus, *Cell* **55**, 619-625 (1988).
8. G. M. Shackleford, C. A. Macarthur, H. C. Kwan, H. E. Varmus, *Proc. Nat. Acad. Sci USA* **90**, 740-744 (1993).
9. H. Roelink, E. Wagenaar, R. Nusse, *Oncogene* **7**, 487-492 (1992).
10. J. A. McMahon, A. P. McMahon, *Development* **107**, 643-650 (1989).
11. H. Roelink, R. Nusse, *Genes Dev.* **5**, 381-388 (1991).
12. B. J. Gavin, J. A. McMahon, A. P. McMahon, *Genes Dev.* **4**, 2319-2332 (1990).
13. N. E. Baker, *EMBO J.* **6**, 1765-1773 (1987).
14. F. Rijsewijk, et al., *Cell* **50**, 649-657 (1987a).
15. P. W. Ingham, *Curr. Opinon in Genetics and Development* **1**, 261-267 (1991).
16. R. Nusse, H. E. Varmus, *Cell* **69**, 1073-1087 (1992).
17. A. P. McMahon, *T.I.G.* **8**, 1-5 (1992).
18. E. Siegfried, E. L. Wilder, N. Perrimon, *Nature* **367**, 76-80 (1994).
19. G. Struhl, K. Basler, *Cell* **72**, 527-540 (1993).
20. J. P. Couso, M. Bate, A. Martinez-Arias, *Science* **259**, 484-490 (1993).
21. Q. Chu-LaGraff, C. Q. Doe, *Science* **261**, 1594-1597 (1993).
22. A. P. McMahon, R. T. Moon, *Cell* **58**, 1075-1084 (1989).
23. J. L. Christian, J. A. McMahon, A. P. McMahon, R. T. Moon, *Development* **111**, 1045-1055 (1991).
24. S. Sokol, J. L. Christian, R. T. Moon, D. A. Melton, *Cell* **67**, 741-752 (1991).
25. W. C. Smith, R. M. Harland, *Cell* **67**, 753-765 (1991).
26. S. Y. Sokol, D. A. Melton, *Dev. Biol.* **154**, 348-356 (1992).
27. B. A. Parr, M. J. Shea, G. Vassileva, A. P. McMahon, *Dev.* **119**, 247-261 (1993).
28. A. P. McMahon, A. Bradley, *Cell* **62**, 1073-1085 (1990).
29. A. P. McMahon, A. L. Joyner, A. Bradley, J. A. McMahon, *Cell* **69**, 581-595 (1992).

30. K. R. Thomas, M. R. Capecchi, *Nature* **346**, 847-850 (1990).
31. K. R. Thomas, T. S. Musci, P. E. Neumann, M. R. Capecchi, *Cell* **67**, 969-976 (1991).
32. J. Zakany, D. Duboule, *Nature* **362**, 546-549 (1993).
33. Y. K. Fung, G. M. Shackleford, A. M. Brown, G. S. Sanders, H. E. Varmus, *Mol. Cell. Biol.* **5**, 3337-3344 (1985).
34. A. M. C. Brown, J. Papkoff, Y. K. Fung, G. M. Shackleford, H. E. Varmus, *Mol. Cell. Biol.* **7**, 3971-3977 (1987).
35. J. Papkoff, A. W. C. Brown, H. E. Varmus, *Mol. Cell. Biol.* **7**, 3978-3984 (1987).
36. J. Kitajewski, J. O. Mason, H. E. Varmus, *Mol. Cell. Biol.* **12**, 784-790 (1992).
37. R. S. Bradley, A. M. C. Brown, *EMBO J.* **9**, 1569-1575 (1990).
38. J. Papkoff, *Mol. Cell. Biol.* **9**, 3377-3384 (1989).
39. J. Papkoff, B. Schryver, *Mol. Cell. Biol.* **10**, 2723-2730 (1990).
40. J. O. Mason, J. Kitajewski, H. E. Varmus, *Mol. Biol. Cell* **3**, 521-533 (1992).
41. S. F. Jue, R. S. Bradley, J. A. Rudnicki, H. E. Varmus, A. M. C. Brown, *Mol. Cell. Biol.* **12**, 321-328 (1992).
42. N. E. Baker, *Dev. Biol.* **125**, 96-108 (1988).
43. N. Parkin, J. Kitajewski, H. E. Varmus, *Genes Dev.* **7**, 2181-2193 (1993).
44. L. W. Burrus, *BioEssays* **16**, 1-3 (1994).
45. M. Peifer, C. Rauskolb, M. Williams, B. Riggleman, E. Wieschaus, *Development* **111**, 1029-1043 (1991).
46. P. D. McCrea, C. W. Turck, B. Gumbiner, *Science* **254**, 1359-1361 (1991).
47. B. M. Gumbiner, P. D. McCrea, *J. Cell. Sci.* **106**, 155-158 (1993).
48. A. M. C. Brown, R. S. Wilden, T. J. Prendergast, H. E. Varmus, *Cell* **46**, 1001-1009 (1986).
49. F. Rijsewijk, L. Deemter, E. Wagenaar, A. Sonneberg, R. Nusse, *EMBO J.* **6**, 127-131 (1987b).
50. J. Mester, E. Wagenaar, M. Sluyser, R. Nusse, *J. Virol.* **61**, 1073-1078 (1987).
51. T. Lin, R. C. Guzman, R. C. Osborn, G. Thordarson, S. Nandi, *Cancer Res.* **52**, 4413-4419 (1992).
52. B. J. Gavin, A. P. McMahon, *Mol. Cell. Biol.* **12**, 2418-2423 (1992).
53. T. A. Buhler, T. C. Dale, C. Kieback, R. C. Humphreys, J. M. Rosen, *Developmental Biology* **155**, 87-96 (1993).
54. I. A. Wilson, et al., *Cell* **37**, 767-778 (1984).
55. A. D. Miller, G. J. Rosman, *Bio. Techniques* **7**, 980-990 (1989).
56. W. S. Pear, G. P. Nolan, M. L. Scott, D. Baltimore, *Proc. Natl. Acad. Sci. USA* **90**, 8392-8396 (1993).
57. A. B. Vaidya, E. Y. Lasfargues, J. B. Sheffield, W. G. Coutinho, *Virology* **90**, 12-22 (1978).
58. E. L. Huguet, J. A. McMahon, A. P. McMahon, R. Bicknell, A. L. Harris, *Cancer Res.* **54**, 2615-2621 (1994).